Rabeprazole

When ATH:
A02BC04

Characteristic.

The substituted benzimidazole derivative. Rabeprazole sodium-a white or slightly yellowish-white substance. Very soluble in water and methanol, Soluble in ethanol, chloroform and ethyl acetate, insoluble in ether and n-hexane. Weak base. Stability depends on the pH is quickly destroyed in moderate acids and is more stable in alkaline Wednesday. Molecular weight 381,43.

Pharmacological action.
Antiulcer.

Application.

Gastric ulcer and duodenal ulcer in the acute stage, helikobakterioz GI (only in combination with other drugs), gastroesophageal reflux disease.

Contraindications.

Hypersensitivity, incl. to substituted benzimidazoles, pregnancy, lactation.

Restrictions apply.

Severe hepatic impairment, childhood (there is no sufficient experience with).

Pregnancy and breast-feeding.

Category actions result in FDA - B. (The study of reproduction in animals revealed no risk of adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not done.)

At the time of treatment should stop breastfeeding.

Side effects.

From the digestive tract: diarrhea, nausea; less frequently is the vomiting, abdominal pain, flatulence, constipation; rarely - dry mouth, belching, dyspepsia; in a few cases, the taste sensations, anorexia, stomatitis, gastritis, increase in transaminases.

From the nervous system and sensory organs: headache; less often, dizziness, asthenia, insomnia; very rarely nervousness, drowsiness; in some cases, depression, visual impairment.

On the part of the musculoskeletal system: rarely, myalgia; very rarely artralgia, leg cramps.

From the respiratory system: rarely is an inflammation or infection of the upper respiratory tract, coughing; very rarely, sinusitis, bronchitis.

Allergic reactions: rarely - rash, itching.

Other: seldom-pain in the back, Breast, limbs, swelling, urinary tract infection, fever, chills, flu-like symptoms; in a few cases, increased sweating, weight gain, leukocytosis.

Cooperation.

It reduces the concentration of ketoconazole in the plasma (on 33%), increases the concentration of digoxin (on 22%). No interaction with liquid antacids. Compatible with drugs, metabolized by the CYP450 system (warfarin, phenytoin, theophylline, diazepam).

Overdose.

Symptoms not disclosed.

Treatment: in cases of suspected overdose encouraged to support and symptomatic therapy. Dialysis nyeeffyektivyen.

Dosing and Administration.

Inside, morning, before meals, without chewing or crushing; When ulcers stomach being increased — 20 mg 1 once a day for 4 Sun, If healing is optional for 4 Sun; When ulcers duodenal ulcer — 10 or 20 mg 1 once a day for 6 Sun, If healing is still 6 Sun; in gastroesophageal reflux disease 20 mg 1 once a day for 4-8 weeks, further possible supportive therapy: 10-20 mg 1 once a day. For infections H. pylori (as part of a triple eradication therapy) -rabeprazol to 20 mg 2 times a day in combination with klaritromitinom 500 mg/day and amoksicillinom 1000 mg / day for 7 days.

Precautions.

Before treatment is necessary to exclude gastric malignancy (symptomatic improvement during therapy with rabeprazole may hamper timely diagnosis). We recommend caution during the first appointment of rabeprazole to patients with severe hepatic impairment. In case of drowsiness must give up driving and other activities, requiring a high concentration. Patients, together with rabeprazole receiving ketoconazole or digoxin, require additional monitoring (It may need a dose adjustment of these drugs).

Cooperation